Market Overview

UPDATE: Credit Suisse Upgrades WuXi PharmaTech to Outperform on Growth Drivers

Related WX
WuXi PharmaTech, PRA Health Sciences Restructure Relationship in China for Delivery of Clinical Trial Management Services
The State Of Chinese Company Take-Private Offers: A Look At WuXi PharmaTech

Credit Suisse raised its rating on WuXi PharmaTech (NYSE: WX) from Neutral to Outperform and increased the price target from $14 to $18.

Credit Suisse noted, "We believe the market under- appreciated WuXi's potential upside from its core growth drivers: (i) Vertically integrated service offerings could benefit more than expected; (ii) Manufacturing business will be scaled-up driven by robust pipelines (four customer drugs move into commercial stage); (iii) Biologics business is on the rise in China, first mover to capture most value (pioneer in setting JV with MNCs such as the AstraZeneca-MedImmune deal)."

WuXi PharmaTech closed at $13.94 on Wednesday.

Latest Ratings for WX

Oct 2015Morgan StanleyDowngradesOverweightEqual-Weight
Mar 2015Goldman SachsDowngradesBuyNeutral
Nov 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (WX)

View Comments and Join the Discussion!

Partner Center